Abstract
Our recent study suggests that targeting GD3 synthase (also known as ST8SIA1)—the rate-limiting enzyme in biosynthesis of the breast cancer stem cell marker GD2—abrogates metastasis and depletes the cancer stem cell populations within a tumor, thus providing an effective therapeutic strategy against metastatic breast cancers.
Author supplied keywords
Cite
CITATION STYLE
APA
Sphyris, N., Sarkar, T. R., Battula, V. L., Andreeff, M., & Mani, S. A. (2015). GD2 and GD3 synthase: novel drug targets for cancer therapy. Molecular and Cellular Oncology, 2(3). https://doi.org/10.4161/23723556.2014.975068
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free